Neoplasia/BPH

	Association of Preoperative Inflammatory Markers With Bladder Stone Recurrence After HoLEP Combined With Lithotripsy in Patients With Benign Prostatic Hyperplasia: A Retrospective Cohort Study. Arch Esp Urol Guo J, Jiang M, Chen J, Ma Z. PMID: 42876136 [PubMed - indexed for MEDLINE]
	Real-World Comparative Effectiveness of Lobaplatin Versus Epirubicin and Gemcitabine for Post-TURBT Intravesical Therapy in Non-Muscle-Invasive Bladder Cancer. Arch Esp Urol Han S, Li X, Ma L, Hu Z, Jia Z, Wu M, Xing N. PMID: 42876134 [PubMed - indexed for MEDLINE]
	Metabolic Syndrome and Bladder Cancer Risk: A Meta-Analysis of Cohort Studies. Arch Esp Urol Teng H, Chen J, Qian J, Chen L, Zhu Y, Tang T, Wang P, Xu X. PMID: 42876132 [PubMed - indexed for MEDLINE]
	Efficacy and Safety of Tranexamic Acid in Endoscopic Surgery for Benign Prostatic Hyperplasia: A TURP-Dominated Systematic Review and Meta-Analysis. Arch Esp Urol Zhang B, Liu J, Zhang Y, Chai Y. PMID: 42876131 [PubMed - indexed for MEDLINE]
	Diagnostic Value of Conventional Ultrasound Combined With Contrast-Enhanced Ultrasound for Differentiating Small Clear Cell and Non-Clear Cell Renal Cell Carcinomas. Arch Esp Urol Zhao J, Xia Y. PMID: 42876128 [PubMed - indexed for MEDLINE]
	Diagnostic Value of Artificial Intelligence-Based Multiparametric MRI for Prostate Cancer in Patients With PSA Levels in the Gray Zone. Arch Esp Urol Mei B, Zhu L, Li Y, Mao X, Dong G. PMID: 42876127 [PubMed - indexed for MEDLINE]
	Evaluation of online dose-guided adaptive fractionation for intact prostate radiotherapy. J Appl Clin Med Phys Gevorkyan GS, Zhu L, Tegtmeier RC, Santos Toesca D, Lu W, Chen M, Rong Y, Chen Q. PMID: 42875902 [PubMed - indexed for MEDLINE]
	Metabolic and oncological effects of metformin added to ADT in prostate cancer: systematic review and meta-analysis including STAMPEDE. Prostate Cancer Prostatic Dis Fakhri F, Alkhairi Z, Sarhan T, Imran G, Imran L, Moola R, Darwish R, Al-Majmuei A. PMID: 42875601 [PubMed - as supplied by publisher]
	Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial. Nat Med Zacchi F, Castro E, Imbach K, Rodriguez-Vida A, Simonetti S, Mellado B, Mir Arnau G, Aguilar D, Castellano D, Climent MA, Ramos MJ, Borque-Fernando A, Guerrero JA, Gonzalez-Alonso P, Perez-Escuredo J, Izquierdo V, Saez MI, Domenech H, Arce-Gallego S, Herrera-Imbroda B, Planas J, Lorente D, Font A, Oliveira A, Cresta Morgado P, Esquefa V, Brandariz J, Anselmino N, Zhu K, Troncoso P, Aguilera M, Vivancos A, Nuciforo P, Casanova-Salas I, Porta E, Carles J, Zurita AJ, Mateo J. PMID: 42875559 [PubMed - as supplied by publisher]
	Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study. Clin Genitourin Cancer Kalebasty AR, Sun J, Tombal B, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Littleton N, Verholen F, Zhang W, Ploeger B, Li R, Zieschang C, Smith MR. PMID: 42875365 [PubMed - as supplied by publisher]
	Aberrant HER2 Expression as a Specific and Feasible Diagnostic Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma. Hum Pathol Hu J, Zhang M, Meng L, Zheng L, Yang Y, Tang J, Pan X, Yin X, Yu T, Nie L, Wei Y, Zhou Q, Chen X, Chen N. PMID: 42874879 [PubMed - as supplied by publisher]
	Periprostatic adipose tissue imaging in prostate cancer: Imaging phenotypes, task-specific spatial strategies, and multicompartment integration-a critical review. Eur J Radiol Huang J, Zhang Y, Yang O, Feng Q, Du H, Gong J, Huang G. PMID: 42874220 [PubMed - as supplied by publisher]
	PANoptosis-Related Molecular Subtyping and a Subtype-Derived Prognostic Signature for Survival Prediction in Clear Cell Renal Cell Carcinoma. Technol Cancer Res Treat Wang X, Shen Y, Du S, Wang H, Xie X, He H. PMID: 42874083 [PubMed - indexed for MEDLINE]
	Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial. J Clin Oncol Solanki AA, Adams W, Proudfoot JA, Baldea K, Barkan GA, Block AM, Desai NB, Farooq A, Folkert MR, Garant A, Gorbonos A, Gupta G, Kang H, Kelly E, Kregel S, Liauw SL, Luminais CK, Mysz M, Quek ML, Showalter TN, Welsh JS, Woods M, Davicioni E, Small W Jr, Harkenrider MM. PMID: 42874014 [PubMed - as supplied by publisher]
	Educational disparities in prostate cancer survival: a retrospective cohort study from Mexico City. Salud Publica Mex Hernández-Pérez JG, Reyes-Morales H, Valenzuela-Sánchez A, Lajous M, Rodríguez-Covarrubias F, Espin-Arellano LI, Morales-Carmona E, Manzanilla-García H, Torres-Sánchez LE. PMID: 42873951 [PubMed - indexed for MEDLINE]
	Dehydrated human amniotic membrane for early return of erectile function after robotic radical prostatectomy: a 10-year journey and lessons learned. J Robot Surg Razdan S, Fathollahi A, Armache A, Razdan S. PMID: 42873363 [PubMed - indexed for MEDLINE]
	Skin-Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real-World Database Study (A Retrospective Cohort Study). Health Sci Rep Hashizume A, Kawahara T, Yamazaki M, Takamoto D, Takeshima T, Kuroda S, Uemura H, Makiyama K, Teranishi JI. PMID: 42871337 [PubMed]
	Omission of lateral isocenter shifts in robust optimization of proton therapy treatment plans for prostate cancer. J Appl Clin Med Phys O'Grady FT, Castro J, Kim DW, Fan J, Wang P. PMID: 42870582 [PubMed - indexed for MEDLINE]
	Prostate Cancer Therapy via Inhibition of Negative Immune Regulation. Biomed Res Int Dutta S, Sengupta P, Chowdhury U, Maldonado Rosas I, Kalita JC, Selvam MKP, Roychoudhury S. PMID: 42870457 [PubMed - indexed for MEDLINE]
	Liquid biopsy in bladder cancer: towards precision oncology. J Transl Med Chen C, Yang Y, Chen Z, Li X, Zhu Y, Zhai Y, Zheng J, Dai X, Zhou JG, Ma H, Ye X. PMID: 42870280 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 192050

Page 1 of 9603



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy